BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37081052)

  • 1. Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos.
    Di Mauro G; Frontini F; Torreggiani E; Iaquinta MR; Caselli A; Mazziotta C; Esposito V; Mazzoni E; Libener R; Grosso F; Maconi A; Martini F; Bononi I; Tognon M
    Sci Rep; 2023 Apr; 13(1):6501. PubMed ID: 37081052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNA-197-3p as a potential biomarker for asbestos exposure.
    Frontini F; Bononi I; Torreggiani E; Di Mauro G; Mazzoni E; Stendardo M; Boschetto P; Libener R; Guaschino R; Grosso F; Guerra G; Martini F; Tognon M
    Sci Rep; 2021 Dec; 11(1):23955. PubMed ID: 34907223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
    PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
    Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
    Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.
    Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD
    Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
    Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
    PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
    Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
    Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATG5 as biomarker for early detection of malignant mesothelioma.
    Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
    BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
    Kirschner MB; Cheng YY; Armstrong NJ; Lin RC; Kao SC; Linton A; Klebe S; McCaughan BC; van Zandwijk N; Reid G
    Mol Oncol; 2015 Mar; 9(3):715-26. PubMed ID: 25497279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
    Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.